European Medicines Agency Myocarditis Workshop Report (January 2023)

In January 2023, the European Medicines Agency (EMA) hosted a workshop on myocarditis post-COVID vaccination. This workshop reviewed the current understanding of the epidemiology, clinical manifestation, and pathophysiology of myocarditis after mRNA COVID vaccination (Spikevax and Comirnaty) or Nuvaxovid, a protein based-vaccine

Click here to view the official summary and relevant documents.

More SAFETY TEMPLATES

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine

June 1, 2023

Brighton Collaboration Safety Template Peer Review Form – Auro Nipah Vaccine

June 8, 2021

Inactivated Viral Vaccines: Standardized Template For Collection Of Key Information For Benefit-Risk Assessment

August 18, 2020

Protein Vaccines: Standardized Template For Collection Of Key Information For Benefit-Risk Assessment

June 11, 2020

Nucleic Acid (RNA And DNA) Vaccines: Standardized Template For Collection Of Key Information For Benefit-Risk Assessment

June 11, 2020
View All

More Posts

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

Âİ Brighton Collaboration  2023. All rights reserved.